The discovery of pharmacodynamic material basis and mechanism of Shuganning injection in treating damp-heat jaundice syndrome: Combining metabolomics and serum pharmacochemistry

IF 3.4 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis Pub Date : 2026-05-15 Epub Date: 2026-01-26 DOI:10.1016/j.jpba.2026.117380

Yanmei He , Xiao Lin , Wanwan Zhong , Xingyan Liu , Xiuyan Yang , Youlian Yao , Meimei Li , Jianyong Zhang

{"title":"The discovery of pharmacodynamic material basis and mechanism of Shuganning injection in treating damp-heat jaundice syndrome: Combining metabolomics and serum pharmacochemistry","authors":"Yanmei He , Xiao Lin , Wanwan Zhong , Xingyan Liu , Xiuyan Yang , Youlian Yao , Meimei Li , Jianyong Zhang","doi":"10.1016/j.jpba.2026.117380","DOIUrl":null,"url":null,"abstract":"<div><div>Shuganning injection (SGNI) is derived from Yinchenhao decoction and has the functions of promoting diuresis, reducing jaundice and protecting the liver. It is primarily utilized in the treatment of liver diseases, particularly damp-heat jaundice. However, the pharmacodynamic material basis and specific mechanisms remain unclear. Therefore, this study aims to elucidate the pharmacodynamic material basis and mechanism of SGNI in the treatment of damp-heat jaundice syndrome (DHJS). High-throughput metabolomics was employed to identify biomarkers associated with DHJS. The migratory prototype components and metabolites present in the blood of SGNI were characterized through serum pharmacochemistry. Correlation analysis was conducted to associate the biomarkers of DHJS with the migrating components in the blood of SGNI, clarifying the pharmacodynamic basis of SGNI in treating DHJS. Furthermore, metabolic pathway enrichment analysis was performed to explore the endogenous core metabolites and key metabolic pathways, providing insights into the mechanism of SGNI in treating DHJS from the metabolic perspective. Finally, a total of 25 metabolites were identified as biomarkers for DHJS, along with 24 prototype migratory components and 38 migratory metabolites of SGNI. It was established that the pharmacodynamic substance basis of SGNI in the treatment of DHJS comprises 15 components. These components primarily exert their effects through key metabolic pathways, including pentose and glucuronate interconversions, arachidonic acid metabolism, and primary bile acid biosynthesis. In conclusion, SGNI demonstrates a significant therapeutic effect on DHJS. It has preliminarily elucidated the pharmacodynamic substance basis and mechanism of action at the metabolic level, offering a scientific foundation for the clinical application and further development of SGNI.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"272 ","pages":"Article 117380"},"PeriodicalIF":3.4000,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708526000488","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Shuganning injection (SGNI) is derived from Yinchenhao decoction and has the functions of promoting diuresis, reducing jaundice and protecting the liver. It is primarily utilized in the treatment of liver diseases, particularly damp-heat jaundice. However, the pharmacodynamic material basis and specific mechanisms remain unclear. Therefore, this study aims to elucidate the pharmacodynamic material basis and mechanism of SGNI in the treatment of damp-heat jaundice syndrome (DHJS). High-throughput metabolomics was employed to identify biomarkers associated with DHJS. The migratory prototype components and metabolites present in the blood of SGNI were characterized through serum pharmacochemistry. Correlation analysis was conducted to associate the biomarkers of DHJS with the migrating components in the blood of SGNI, clarifying the pharmacodynamic basis of SGNI in treating DHJS. Furthermore, metabolic pathway enrichment analysis was performed to explore the endogenous core metabolites and key metabolic pathways, providing insights into the mechanism of SGNI in treating DHJS from the metabolic perspective. Finally, a total of 25 metabolites were identified as biomarkers for DHJS, along with 24 prototype migratory components and 38 migratory metabolites of SGNI. It was established that the pharmacodynamic substance basis of SGNI in the treatment of DHJS comprises 15 components. These components primarily exert their effects through key metabolic pathways, including pentose and glucuronate interconversions, arachidonic acid metabolism, and primary bile acid biosynthesis. In conclusion, SGNI demonstrates a significant therapeutic effect on DHJS. It has preliminarily elucidated the pharmacodynamic substance basis and mechanism of action at the metabolic level, offering a scientific foundation for the clinical application and further development of SGNI.

查看原文本刊更多论文

舒肝宁注射液治疗湿热黄疸证的药效学、物质基础及作用机制的发现：代谢组学与血清药物化学的结合

舒肝宁注射液（SGNI）是由银陈好汤衍生而来，具有利尿、降黄疸、护肝的作用。它主要用于治疗肝脏疾病，特别是湿热黄疸。然而，其药效学、物质基础和具体机制尚不清楚。因此，本研究旨在阐明SGNI治疗湿热黄疸综合征（DHJS）的药效学、物质基础及作用机制。采用高通量代谢组学方法鉴定与DHJS相关的生物标志物。通过血清药物化学对SGNI在血液中的迁移原型成分和代谢物进行了表征。通过相关分析，将DHJS生物标志物与SGNI血液中迁移组分进行关联，明确SGNI治疗DHJS的药效学基础。通过代谢途径富集分析，探索内源性核心代谢物和关键代谢途径，从代谢角度深入了解SGNI治疗DHJS的机制。最后，共鉴定出25种代谢物作为DHJS的生物标志物，以及24种原型迁移组分和38种SGNI迁移代谢物。确定SGNI治疗DHJS的药效学物质基础由15个组分组成。这些成分主要通过关键的代谢途径发挥作用，包括戊糖和葡萄糖醛酸的相互转化、花生四烯酸代谢和初级胆汁酸的生物合成。综上所述，SGNI对DHJS有显著的治疗作用。初步阐明了代谢水平的药效学、物质基础和作用机制，为SGNI的临床应用和进一步开发提供了科学依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of pharmaceutical and biomedical analysis 医学-分析化学

CiteScore

6.70

自引率

5.90%

发文量

588

审稿时长

37 days

期刊介绍： This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome. Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.